IFW

Attorney Docket No.: 38005-0197

Application No.: 10/820,736

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

he Application of

Lothar SCHWINK et al.

Application No.: 10/820,736

Group Art Unit: Unassigned

Filed: April 9, 2004 : Examiner: Unassigned

For: AMINOALKYL-SUBSTITUTED AROMATIC

BICYCLIC COMPOUNDS, METHODS FOR THEIR PREPARATION AND THEIR USE AS

PHARMACEUTICALS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56 AND 1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

To comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §§1.56 and 1.97, Applicants submit herewith on Form PTO/SB/08A a listing of documents known to Applicants. A copy of each of the listed documents is being submitted to comply with the provisions of 37 C.F.R. §§ 1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b).

Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima* facie prior art reference against the claims of the present application.

Attorney Docket No.: 38005-0197 Application No.: 10/820,736

The undersigned hereby states in accordance with 37 C.F.R. §1.97(e)(1) that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three 3) months prior to the filing of this Information Disclosure Statement. Therefore, Applicants believe that no fee is required. However, if a fee is required, Applicants authorize the USPTO to charge any fees to Deposit Account No. 08-1642, referencing Docket No. 38005-0197.

Applicants respectfully request that the listed documents be considered by the Examiner and made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: July 9, 2004

Patricia D. Granados Attorney for Applicant Registration No.: 33,683

Heller Ehrman White & McAuliffe LLP 1666 K Street, N.W., Suite 300 Washington, D.C. 20006-1228 Telephone: (202) 912-2000

Facsimile: (202) 912-2020 **Customer No. 26633**

dc146585v1

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 10/820,736 Application Number INFORMATION DISCLOSURE Filing Date April 9, 2004 STATEMENT BY APPLICANT Lothar Schwink et al. First Named Inventor Unassigned Group Art Unit (use as many sheets as necessary) **Examiner Name** Unassigned of Attorney Docket Number 38005-0197

Examiner Cite No.1	2		Cited Document	
	Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Releva Passages or Relevant Figures Appear
1.	US-4,405,644	09-20-1983	Kabbe et al.	
2.	US-5,756,496	05-26-1998	Ham et al.	
3.	US-6,310,107	10-30-2001	Kato et al.	

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
	4.	DD 29 28 584	01/29/1981	Bayer AG		
	5.	WO 01/82925	11/8/2001	Takeda Chemical Industries, Ltd.		
				0		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	6.	US Patent Application Publication No. 2004/0077628 A1 by Ishihara et al., "Melanin-Concentrating Hormone Antagonist", based on PCT/JP01/03614, assigned to Takeda Pharmaceuticals North America, Inc., published April 22, 2004.		

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to filed (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.